相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Serum Neurofilament Light Chain Levels in Patients With Presymptomatic Multiple Sclerosis
Kjetil Bjornevik et al.
JAMA NEUROLOGY (2020)
Serum neurofilament light chain level associations with clinical and cognitive performance in multiple sclerosis: A longitudinal retrospective 5-year study
Dejan Jakimovski et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Neurofilament light levels are associated with long-term outcomes in multiple sclerosis
Jens Kuhle et al.
MULTIPLE SCLEROSIS JOURNAL (2020)
Blood neurofilament light levels segregate treatment effects in multiple sclerosis
Benedicte Delcoigne et al.
NEUROLOGY (2020)
Serum neurofilament light levels in normal aging and their association with morphologic brain changes
Michael Khalil et al.
NATURE COMMUNICATIONS (2020)
Blood neurofilament light chain as a biomarker of MS disease activity and treatment response
Jens Kuhle et al.
NEUROLOGY (2019)
Blood neurofilament light as a potential endpoint in Phase 2 studies in MS
Maria Pia Sormani et al.
ANNALS OF CLINICAL AND TRANSLATIONAL NEUROLOGY (2019)
Cerebrospinal fluid neurofilament light chain predicts disease activity after the first demyelinating event suggestive of multiple sclerosis
Lorenzo Gaetani et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Establishment of neurofilament light chain Simoa assay in cerebrospinal fluid and blood
Robert Hendricks et al.
BIOANALYSIS (2019)
Association Between Serum Neurofilament Light Chain Levels and Long-term Disease Course Among Patients With Multiple Sclerosis Followed up for 12 Years
Ester Canto et al.
JAMA NEUROLOGY (2019)
No evidence of disease activity status over 3 years in a real-world cohort of relapsing remitting MS patients in Germany
Konstantin Huhn et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2019)
Serum neurofilament as a predictor of disease worsening and brain and spinal cord atrophy in multiple sclerosis
Christian Barro et al.
BRAIN (2018)
Multiple Sclerosis
Daniel S. Reich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The evolution of No Evidence of Disease Activity in multiple sclerosis
G. Lu et al.
MULTIPLE SCLEROSIS AND RELATED DISORDERS (2018)
Neurofilaments as biomarkers in neurological disorders
Michael Khalil et al.
NATURE REVIEWS NEUROLOGY (2018)
Long-term outcomes of peginterferon beta-1a in multiple sclerosis: results from the ADVANCE extension study, ATTAIN
Scott D. Newsome et al.
THERAPEUTIC ADVANCES IN NEUROLOGICAL DISORDERS (2018)
Neurofilament light chain predicts disease activity in relapsing-remitting MS
Kristin N. Varhaug et al.
NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION (2018)
Serum neurofilament is associated with progression of brain atrophy and disability in early MS
Jens Kuhle et al.
NEUROLOGY (2017)
Monitoring disease activity in multiple sclerosis using serum neurofilament light protein
Lenka Novakova et al.
NEUROLOGY (2017)
Serum Neurofilament Light: A Biomarker of Neuronal Damage in Multiple Sclerosis
Giulio Disanto et al.
ANNALS OF NEUROLOGY (2017)
Revised Recommendations of the Consortium of MS Centers Task Force for a Standardized MRI Protocol and Clinical Guidelines for the Diagnosis and Follow-Up of Multiple Sclerosis
A. Traboulsee et al.
AMERICAN JOURNAL OF NEURORADIOLOGY (2016)
Association of Cerebrospinal Fluid Neurofilament Light Concentration With Alzheimer Disease Progression
Henrik Zetterberg et al.
JAMA NEUROLOGY (2016)
EVIDENCE-BASED GUIDELINES MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis-establishing disease prognosis and monitoring patients
Mike P. Wattjes et al.
NATURE REVIEWS NEUROLOGY (2015)
Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis
Ernst-Wilhelm Radue et al.
NEUROLOGY (2015)
Peginterferon beta-1a in multiple sclerosis: 2-year results from ADVANCE
Bernd C. Kieseier et al.
MULTIPLE SCLEROSIS JOURNAL (2015)
Systematic literature review and validity evaluation of the Expanded Disability Status Scale (EDSS) and the Multiple Sclerosis Functional Composite (MSFC) in patients with multiple sclerosis
Sandra Meyer-Moock et al.
BMC NEUROLOGY (2014)
Pegylated interferon beta-1a for relapsing-remitting multiple sclerosis (ADVANCE): a randomised, phase 3, double-blind study
Peter A. Calabresi et al.
LANCET NEUROLOGY (2014)
Neurofilament light antibodies in serum reflect response to natalizumab treatment in multiple sclerosis
Sandra Amor et al.
MULTIPLE SCLEROSIS JOURNAL (2014)
Defining the clinical course of multiple sclerosis The 2013 revisions
Fred D. Lublin et al.
NEUROLOGY (2014)
The measurement and clinical relevance of brain atrophy in multiple sclerosis
RA Bermel et al.
LANCET NEUROLOGY (2006)
Short-term brain volume change in relapsing-remitting multiple sclerosis - Effect of glatiramer acetate and implications
M Rovaris et al.
BRAIN (2001)
分享论文
